News briefing: Gilead reveals more filgotinib data; Seagen and Astellas report new cohort for Padcev
Two months after being rejected by the FDA, Gilead still hasn’t decided what to do with filgotinib. And now they have
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
